The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: A target for PI-3 kinase inhibitor intervention

Susan K. Peirce, Harry W. Findley, Chengyu Prince, Anindya Dasgupta, Todd Cooper, Donald L. Durden

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Studies of SF1126, an RGDS targeted, water-soluble prodrug of LY294002, are currently nearing completion in two adult Phase I trials. Herein, we performed a preclinical evaluation of SF1126 as a PI-3K inhibitor for Phase I trials in the treatment of recurrent neuroblastoma (NB). Methods: The effects of SF1126 on pAkt-MDM2 cell signaling, proliferation, apoptosis, and migration were determined using a panel of NB cell lines, and anti-tumor activity was determined using a xenograft model of NB. Results: SF1126 blocks MDM2 activation, IGF-1 induced activation of Akt, and the upregulation of survivin induced by IGF-1. It also increases sensitivity to doxorubicin in vitro and was found to exhibit marked synergistic activity in combination with doxorubicin. Treatment disrupts the integrin αvβ3/αvβ5-mediated organization of the actin cytoskeleton as well as the α4β1/ α5β1-mediated processes essential to metastasis. In vivo, SF1126 markedly inhibits tumor growth in NB xenografted mice (P < 0.05). Conclusions: A pan PI-3 kinase inhibitor has potent antitumor activity and induces apoptosis in multiple neuroblastoma cell lines. The observed effects of SF1126 on the p-Akt-MDM2-survivin axis suggest a patient selection paradigm in which NB tumors with increased pAkt-MDM2-survivin signaling may predict response to SF1126 alone or in combination with standard chemotherapy regimens that contain anthracyclines.

Original languageEnglish (US)
Pages (from-to)325-335
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number2
DOIs
StatePublished - Aug 1 2011

Fingerprint

Neuroblastoma
Phosphatidylinositol 3-Kinases
Tumors
Insulin-Like Growth Factor I
Doxorubicin
Chemical activation
Cells
Apoptosis
Cell signaling
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Chemotherapy
Anthracyclines
Prodrugs
SF 1126
Tumor Cell Line
Actin Cytoskeleton
Heterografts
Integrins
Patient Selection
Actins

Keywords

  • MDM2
  • Neuroblastoma
  • Pan PI3-kinase inhibitor
  • SF1126
  • Survivin

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma : A target for PI-3 kinase inhibitor intervention. / Peirce, Susan K.; Findley, Harry W.; Prince, Chengyu; Dasgupta, Anindya; Cooper, Todd; Durden, Donald L.

In: Cancer Chemotherapy and Pharmacology, Vol. 68, No. 2, 01.08.2011, p. 325-335.

Research output: Contribution to journalArticle

Peirce, Susan K. ; Findley, Harry W. ; Prince, Chengyu ; Dasgupta, Anindya ; Cooper, Todd ; Durden, Donald L. / The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma : A target for PI-3 kinase inhibitor intervention. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 68, No. 2. pp. 325-335.
@article{bc798e3384074d998d080de4e7999359,
title = "The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: A target for PI-3 kinase inhibitor intervention",
abstract = "Purpose: Studies of SF1126, an RGDS targeted, water-soluble prodrug of LY294002, are currently nearing completion in two adult Phase I trials. Herein, we performed a preclinical evaluation of SF1126 as a PI-3K inhibitor for Phase I trials in the treatment of recurrent neuroblastoma (NB). Methods: The effects of SF1126 on pAkt-MDM2 cell signaling, proliferation, apoptosis, and migration were determined using a panel of NB cell lines, and anti-tumor activity was determined using a xenograft model of NB. Results: SF1126 blocks MDM2 activation, IGF-1 induced activation of Akt, and the upregulation of survivin induced by IGF-1. It also increases sensitivity to doxorubicin in vitro and was found to exhibit marked synergistic activity in combination with doxorubicin. Treatment disrupts the integrin αvβ3/αvβ5-mediated organization of the actin cytoskeleton as well as the α4β1/ α5β1-mediated processes essential to metastasis. In vivo, SF1126 markedly inhibits tumor growth in NB xenografted mice (P < 0.05). Conclusions: A pan PI-3 kinase inhibitor has potent antitumor activity and induces apoptosis in multiple neuroblastoma cell lines. The observed effects of SF1126 on the p-Akt-MDM2-survivin axis suggest a patient selection paradigm in which NB tumors with increased pAkt-MDM2-survivin signaling may predict response to SF1126 alone or in combination with standard chemotherapy regimens that contain anthracyclines.",
keywords = "MDM2, Neuroblastoma, Pan PI3-kinase inhibitor, SF1126, Survivin",
author = "Peirce, {Susan K.} and Findley, {Harry W.} and Chengyu Prince and Anindya Dasgupta and Todd Cooper and Durden, {Donald L.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1007/s00280-010-1486-7",
language = "English (US)",
volume = "68",
pages = "325--335",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma

T2 - A target for PI-3 kinase inhibitor intervention

AU - Peirce, Susan K.

AU - Findley, Harry W.

AU - Prince, Chengyu

AU - Dasgupta, Anindya

AU - Cooper, Todd

AU - Durden, Donald L.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Purpose: Studies of SF1126, an RGDS targeted, water-soluble prodrug of LY294002, are currently nearing completion in two adult Phase I trials. Herein, we performed a preclinical evaluation of SF1126 as a PI-3K inhibitor for Phase I trials in the treatment of recurrent neuroblastoma (NB). Methods: The effects of SF1126 on pAkt-MDM2 cell signaling, proliferation, apoptosis, and migration were determined using a panel of NB cell lines, and anti-tumor activity was determined using a xenograft model of NB. Results: SF1126 blocks MDM2 activation, IGF-1 induced activation of Akt, and the upregulation of survivin induced by IGF-1. It also increases sensitivity to doxorubicin in vitro and was found to exhibit marked synergistic activity in combination with doxorubicin. Treatment disrupts the integrin αvβ3/αvβ5-mediated organization of the actin cytoskeleton as well as the α4β1/ α5β1-mediated processes essential to metastasis. In vivo, SF1126 markedly inhibits tumor growth in NB xenografted mice (P < 0.05). Conclusions: A pan PI-3 kinase inhibitor has potent antitumor activity and induces apoptosis in multiple neuroblastoma cell lines. The observed effects of SF1126 on the p-Akt-MDM2-survivin axis suggest a patient selection paradigm in which NB tumors with increased pAkt-MDM2-survivin signaling may predict response to SF1126 alone or in combination with standard chemotherapy regimens that contain anthracyclines.

AB - Purpose: Studies of SF1126, an RGDS targeted, water-soluble prodrug of LY294002, are currently nearing completion in two adult Phase I trials. Herein, we performed a preclinical evaluation of SF1126 as a PI-3K inhibitor for Phase I trials in the treatment of recurrent neuroblastoma (NB). Methods: The effects of SF1126 on pAkt-MDM2 cell signaling, proliferation, apoptosis, and migration were determined using a panel of NB cell lines, and anti-tumor activity was determined using a xenograft model of NB. Results: SF1126 blocks MDM2 activation, IGF-1 induced activation of Akt, and the upregulation of survivin induced by IGF-1. It also increases sensitivity to doxorubicin in vitro and was found to exhibit marked synergistic activity in combination with doxorubicin. Treatment disrupts the integrin αvβ3/αvβ5-mediated organization of the actin cytoskeleton as well as the α4β1/ α5β1-mediated processes essential to metastasis. In vivo, SF1126 markedly inhibits tumor growth in NB xenografted mice (P < 0.05). Conclusions: A pan PI-3 kinase inhibitor has potent antitumor activity and induces apoptosis in multiple neuroblastoma cell lines. The observed effects of SF1126 on the p-Akt-MDM2-survivin axis suggest a patient selection paradigm in which NB tumors with increased pAkt-MDM2-survivin signaling may predict response to SF1126 alone or in combination with standard chemotherapy regimens that contain anthracyclines.

KW - MDM2

KW - Neuroblastoma

KW - Pan PI3-kinase inhibitor

KW - SF1126

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=79960924027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960924027&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1486-7

DO - 10.1007/s00280-010-1486-7

M3 - Article

C2 - 20972874

AN - SCOPUS:79960924027

VL - 68

SP - 325

EP - 335

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -